Roctavian

Aug 22, 2025

Over the past four decades, hemophilia A treatment has advanced remarkably. Beginning with the introduction of cryoprecipitate in 1964, treatment progressed to plasma-derived FVIII, then to recombinant FVIII therapies in the 1980s. The 1990s and 2000s saw the rise of Standard Half-life (SHL) products, followed by E...

Feb 05, 2024

Gene therapy is an innovative medical approach that manipulates an individual’s genetic material to prevent or treat diseases. It primarily involves introducing, modifying, or substituting genes within a patient’s cells. The central objective of gene therapy is to rectify genetic abnormalities, insert missing genes...

Jul 14, 2023

Hemophilia A is a rare genetic bleeding disorder that primarily affects males. Hemophilia A is the most common type of hemophilia, accounting for approximately 80% of all cases. It is estimated to occur in about 1 in 5,000 to 10,000 male births. As per the Centers for Disease Control (CDC) (2020), the estimated pre...